Idorsia (CHIX:IDIAZ) Change In Receivables : CHF-1.4 Mil (TTM As of Mar. 2025)

View and export this data going back to 2017. Start your Free Trial

What is Idorsia Change In Receivables?

Idorsia's change in receivables for the quarter that ended in Mar. 2025 was CHF3.3 Mil. It means Idorsia's Accounts Receivable declined by CHF3.3 Mil from Dec. 2024 to Mar. 2025 .

Idorsia's change in receivables for the fiscal year that ended in Dec. 2024 was CHF-6.0 Mil. It means Idorsia's Accounts Receivable increased by CHF6.0 Mil from Dec. 2023 to Dec. 2024 .

Idorsia's Accounts Receivable for the quarter that ended in Mar. 2025 was CHF33.9 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Idorsia's Days Sales Outstanding for the three months ended in Mar. 2025 was 52.48.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Idorsia's liquidation value for the three months ended in Mar. 2025 was CHF-1,466.9 Mil.

Idorsia Change In Receivables Historical Data

The historical data trend for Idorsia's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Idorsia Change In Receivables Chart

Idorsia Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Change In Receivables

Get a 7-Day Free Trial

2.73

-6.27

-33.90

-12.88

-5.99

Idorsia Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Change In Receivables	Get a 7-Day Free Trial															-1.30	-0.38	4.60	-8.92	3.29

Idorsia Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF-1.4 Mil.

Idorsia (CHIX:IDIAz) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Idorsia's Days Sales Outstanding for the quarter that ended in Mar. 2025 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	33.868	/	58.883	*	91
=	52.48

2. In Ben Graham's calculation of liquidation value, Idorsia's accounts receivable are only considered to be worth 75% of book value:

Idorsia's liquidation value for the quarter that ended in Mar. 2025 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	64.847	-	1588.352	+	0.75 * 33.868	+	0.5 * 62.468
=	-1,466.9

Idorsia Change In Receivables Related Terms

Thank you for viewing the detailed overview of Idorsia's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Idorsia Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Idorsia Ltd (CHIX:IDIAz) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

IDRSF:USA 0RQE:UK IDIA:Switzerland

Address

Hegenheimermattweg 91, Allschwil, CHE, 4123

Website

https://www.idorsia.com

Idorsia Ltd is a biopharmaceutical company engaged in discovering, developing, and commercializing of medicines for unmet medical needs. It is a biotech hub of Europe specialized in the discovery and development of small molecules, to provide innovative therapeutic options. The company focuses on multiple therapeutic areas which include the central nervous system, cardiovascular disorders, immunological disorders, and orphan diseases. Idorsia's development compounds target a number of different diseases such as Resistant Hypertension, lupus, insomnia, Cerebral vasospasm, and Fabry disease. Geographically, it derives revenue from Switzerland.

Idorsia Headlines

No Headlines